The Multi-Stage Vectors (MSV), mesoporous silicon particles, serve as an 'integrator', and vectoring function for single types and multiple-type combinations of the nanoparticles. The MSVs are present in all TCCN projects. MSVs are manufactured using photolithographic and electrochemical methods developed by the Ferrari group in a National nanotechnology core facility at the University of Texas in Austin, where Dr. Ferrari maintains a team of 12 personnel coordinated by TCCN investigator Assistant Professor Xuewu Liu. The manufacture of MSVs involves highly specialized equipment and very complex multi-step protocols. Therefore, it is necessary to establish the mesoporous silicon-producing operation ofthe TCCN as a Nanoengineering Core, directed by Dr. Ferrari, in collaboration with Dr. West for what pertains to the integration of second-stage nanoparticles in the MSVs, and Dr. Liu. In addition to the particulate systems, the Nanoengineering Core will manufacture and characterize the mesoporous silica nanochips for proteomics and peptidomlcs, which are utilized in all TCCN projects for the monitoring of therapeutic and preventative efficacy, and the identification of multi-molecular signature markers for the early detection of ovarian and pancreatic cancer. These nanochips were also developed by the Ferrari group in the National nanotechnology core facility in Austin.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151668-03
Application #
8382372
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
3
Fiscal Year
2012
Total Cost
$156,707
Indirect Cost
$39,059
Name
University of Texas Health Science Center Houston
Department
Type
DUNS #
800771594
City
Houston
State
TX
Country
United States
Zip Code
77225
Wagner, Michael J; Mitra, Rahul; McArthur, Mark J et al. (2017) Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA). Mol Cancer Ther 16:1114-1123
Samuelsson, Emma; Shen, Haifa; Blanco, Elvin et al. (2017) Contribution of Kupffer cells to liposome accumulation in the liver. Colloids Surf B Biointerfaces 158:356-362
Zhou, Jinhua; Alfraidi, Albandri; Zhang, Shu et al. (2017) A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clin Cancer Res 23:1945-1954
Venuta, Alessandro; Wolfram, Joy; Shen, Haifa et al. (2017) Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B 5:207-219
Wolfram, Joy; Nizzero, Sara; Liu, Haoran et al. (2017) A chloroquine-induced macrophage-preconditioning strategy for improved nanodelivery. Sci Rep 7:13738
Pi, Fengmei; Zhang, Hui; Li, Hui et al. (2017) RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery. Nanomedicine 13:1183-1193
Zacharias, Niki Marie; McCullough, Christopher; Shanmugavelandy, Sriram et al. (2017) Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer. Sci Rep 7:16159
Borsoi, Carlotta; Leonard, Fransisca; Lee, Yeonju et al. (2017) Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett 403:296-304
Van Roosbroeck, Katrien; Fanini, Francesca; Setoyama, Tetsuro et al. (2017) Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res 23:2891-2904
Kanlikilicer, Pinar; Ozpolat, Bulent; Aslan, Burcu et al. (2017) Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models. Mol Ther Nucleic Acids 9:251-262

Showing the most recent 10 out of 325 publications